Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review
Kahn, J.S..; Casseres, R.G..; Her, M.J..; Dumont, N.; Gottlieb, A.B..; Rosmarin, D.
Journal of Drugs in Dermatology: Jdd 18(4)
2019
ISSN/ISBN: 1545-9616 PMID: 31013012 Document Number: 17768
Introduction: Biologics have transformed the management of moderate-to-severe psoriasis. The risk of developing a malignancy during treatment is an important consideration, and many studies have been conducted to determine the magnitude of this risk. However, there is little research on the use of biologic treatment in psoriasis patients with a history of established malignancy.
Document emailed within 1 workday
